MaNGO
Mario Negri Gynecologic Oncology

XVIII ASSEMBLEA MANGO

Ricerca Clinica e Traslazionale in Ginecologia Oncologica

MILANO, 2-3 LUGLIO 2021

Con il Patrocinio di:

AIOM Associazione Italiana di Oncologia Medica

FICOG | Federation of Italian Cooperative Oncology Groups

SOCIETA' ITALIANA DI CANCEROLOGIA

SIGO SOCIETA' ITALIANA DI GINECOLOGIA E OSTETRICIA

ACTO ALLEANZA CONTRO il TUMORE OVARICO

Studio AtTEnd

Phase III double-blind randomized trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Study update

Anna Roberto on behalf of the AtTEnd study team
Laboratorio di Metodologia per la ricerca clinica
Istituto di Ricerche Farmacologiche Mario Negri IRCCS

MaNGO
Ricerca Clinica e Traslazionale in Ginecologia Oncologica
XVIII ASSEMBLEA MANGO
MILANO, 2-3 LUGLIO 2021

STUDY DESIGN

ENGOT model: A



Stratified by:

- Country of the experimental center
- Histological type (endometrioid vs. other types)
- Disease (recurrent disease vs advanced disease at primary diagnosis)
- MS status (MSS vs MSI vs non-evaluable)

Primary objective: OS and PFS

Secondary objectives: PFS in MSI, PFS2, RR, QoL, safety, PK, ADA, ct-DNA

PI: Nicoletta Colombo, European Institute of Oncology (IEO)

Sponsor: Mario Negri Gynecologic Oncology (MaNGO)/ **Supporter:** F. Hoffmann-La Roche Ltd, Chugai Pharma. Co. Ltd

OVERVIEW ON GLOBAL STUDY ACTIVATION

Participating Groups:

MaNGO – Italy
A-AGO – Austria
AGO – GermanyGEICO – Spain
NCRI – UK
SAKK – Switzerland

ANZGOG – Australia New Zealand
JGOG – Japan
KGOG – Korea

Last collaboration finalized:
TGOG – Taiwan: first activation planned for July 2021

Sites overall: 88 open sites/102 involved (86%)



MaNGO
Ricerca Clinica e Traslazionale in Ginecologia Oncologica

OVERVIEW ON GLOBAL ENROLLMENT STATUS



As of July 1st 2021:

- No. of randomized patients: 410
- No. of screen failures: 86 (16%)
- No. of pts under screening: 30

OVERVIEW ON GLOBAL ENROLLMENT STATUS



Official enrolment extension up to September 2021

Further prolongation up to Dec 2021/Jan 2022

ENROLMENT BY COUNTRY AND COMMITMENT



Current Committment	Accrual/ commitment %	
158	100%	Enrolment until global LPI
60	100%	Enrolment until global LPI
60	100%	Further 20 patients
43	90%	Activation delay/Reduced initial commitment
40	65%	Activation delay/Reduced initial commitment
NA	NA	Accrual closed by SAKK board Nov-2020
20	80%	Enrolment until global LPI
6	100%	Under performing, no important impact
40	5%	Activated in May, FPI in June

Taiwan: 40 patients/year FPI in September

ENROLLMENT BY ITALIAN SITES



COMPETITIVE ENVIRONMENT

Open trials with competitive countries

- **DUO-E**: efficacy and safety of durvalumab + chemo (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer

- **RUBY – Part 2**: efficacy and safety of dostarlimab + chemo (carboplatin-paclitaxel) followed by dostarlimab plus niraparib versus placebo + chemo (carboplatin-paclitaxel) followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer

COMPETITIVE ENVIRONMENT

Closed trials - no longer competitive for recruitment:

- **RUBY – Part 1**: efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo. **After 1 prior platinum chemo**

- **LEAP-001**: to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in Stage III, IV, or recurrent endometrial carcinoma. **As first-line**

- **KEYNOTE-775**: pembrolizumab in combination with lenvatinib versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. **After 1 prior platinum chemo**

NEW EVIDENCES

KEYNOTE-775: pembro+lenva vs. physician's choice (doxorubicin or paclitaxel) for treatment of advanced EC.

827 patients

improvement in PFS (pMMR and dMMR) reducing the risk of disease progression or death by 44% with a median PFS of 7.2 months versus 3.8 months

improvement in OS (pMMR and dMMR) reducing the risk of death by 38% with a median OS of 18.3 months versus 11.4 months

Regardless MMR status

FDA Grants Priority Review to Pembrolizumab Plus Lenvatinib in Advanced RCC and Endometrial Cancer

No.21-22

March 30, 2021
Eisai Co., Ltd.

EUROPEAN MEDICINES AGENCY ACCEPTS THE MARKETING AUTHORISATION APPLICATIONS FOR TWO ADDITIONAL INDICATIONS OF ANTI CANCER AGENT LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA AND ADVANCED ENDOMETRIAL CARCINOMA

GARNET: pembro+lenva vs. physician's choice (doxorubicin or paclitaxel) for treatment of advanced EC.

108 patients with recurrent or advanced dMMR/MSI-H EC who progressed on or post-platinum containing chemotherapy
ORR=43.5%
Disease control rate=55.6%

The European Commission has granted conditional marketing authorization to dostarlimab for the treatment of patients with microsatellite instability–high/mismatch repair deficient recurrent or advanced endometrial cancer who have progressed on or following prior therapy with a platinum-containing regimen.

AMENDMENT STATUS UPDATE

Ongoing - Protocol v 4.0: Blood samples collection to evaluate the atezolizumab Pharmacokinetics, to determin the Anti-Therapeutic Antibody levels, and to identify the ct-DNA (as predictive/prognostic biomarker) – submitted last October

Site	Contract status
Milano - PI Colombo	Signed
Brescia - PI Tognon	Signed
Lucca - PI Baldini	Signed
Bologna - PI Zamagni	Signed
Brescia - PI Abeni	Signed
Lecco - PI Ardizzoia	Signed
Sora - PI Narducci	Signed
Firenze - PI Antonuzzo	Signed
Rimini - PI Arcangeli	Signed
Ravenna - PI Arcangeli	Signed
Torino - PI Zola	Under signature
Sondrio - PI Bertolini	Under signature
Alessandria - PI Fusco	Under signature
Roma - PI Panici	Under signature finalization

Site	Contract status
Torino - PI Ferrero	Under Site review
Parma - PI Musolino	Under Site review
Monza - PI Lissoni	Under Site review
Padova - PI Tasca	Under Site review
Reggio Emilia - PI Bologna	Under Site review
Vercelli - PI De Marino	Under Site review
Bolzano - PI Lusso	Under Sponsor review
Cagliari - PI Massa	Under Sponsor review
Pisa - PI Gadducci	Under Sponsor review
Genova - PI De Censi	EC approval pending
Como - PI Giordano	EC approval pending

AMENDMENT STATUS UPDATE

Protocol v 5.0 - Submitted on May and already approved by AIFA

Update of the protocol according to:

- **New safety information (DIL 24 Oct 2020 on Severe Cutaneous Adverse Reactions and new IB v.17)**
- **New statistical design anticipating the PFS final analysis at the time of OS interim analysis (green light from IDMC and SC members)**
- **Addition two futility analyses (OS and PFS)**
- **Study prolongation with new timing for interim and final analyses**

In Italy 3 sites have been added:

- **Ospedale Metropolitano Niguarda di Milano (PI Carlo Stella)**
- **Istituto Nazionale dei Tumori di Milano (PI Raspagliesi)**
- **ASST del Garda di Manerbio (PI Montani)**


Thank you!